Last reviewed · How we verify
NCT07424508
Movement State-dependent Adaptive DBS for PD
NA trial testing Summit RC+S in Parkinson's Disease (PD) in 6 participants. Enrolling by invitation.
1 April 2026
Quick facts
| Lead sponsor | Doris Wang, MD, PhD |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 4 February 2026 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Summit RC+S
- Summit RC+S
Conditions studied
- Parkinson's Disease (PD) — all drugs for Parkinson's Disease (PD) →
Sponsor
Doris Wang, MD, PhD
Who can join
Adults 21 to 75, any sex, with Parkinson's Disease (PD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center clinical study aiming to improve gait functions in patients with Parkinson's Disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capabilities to 1) identify neural biomarkers to detect the onset of walking by recording neural activities from the motor cortical areas and the globus pallidus, 2) understand the impacts of changes in DBS parameters on gait kinematics and optimize setting parameters for enhancing walking performance, 3) develop a movement state-dependent adaptive deep brain stimulation (DBS) paradigm to automatically switch stimulation settings according to different movement states (i.e., walking vs non-walking). The proposed therapy will deliver personalized neurostimulation based on individual physiological biomarkers to enhance gait function in patients with PD. 6 patients with idiopathic Parkinson's disease who have already been implanted with the Medtronic Summit RC+S device will be enrolled in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07424508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Summit RC+S
Trials testing the same drug.
- NCT04675398 — Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease · NA · active not recruiting
Other recruiting trials for Parkinson's Disease (PD)
Currently open trials in the same condition.
- NCT07322887 — A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreate · Phase 2 · recruiting
- NCT07348705 — Electrophysiology-based DBS Programming for PD · NA · recruiting
- NCT07316296 — Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi · Phase 3 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07310264 — Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease · Phase 1 · recruiting
Other Doris Wang, MD, PhD trials
Trials by the same sponsor.
- NCT06819020 — Adaptive Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease · NA · enrolling by invitation
- NCT04675398 — Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07424508 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Doris Wang, MD, PhD
- Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07424508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing